Results 41 to 50 of about 19,815 (203)

Clinical implications of discordant early molecular responses in CML patients treated with imatinib [PDF]

, 2019
A reduction in BCR-ABL1/ABL1IS transcript levels to <10% after 3 months or <1% after 6 months of tyrosine kinase inhibitor therapy are associated with superior clinical outcomes in chronic myeloid leukemia (CML) patients.
Accurso V., Antolino A., Di Raimondo F., Forte S., Impera S., Malato A., Mannina D., Manzella L., Martino B., Massimino M., Mineo G., Musolino C., Musso M., Pennisi M. S., Porretto F., Russo S., Siragusa S., Spitaleri A., Stagno F., Stella S., Tirro E., Vigneri P., Vitale S. R., Zammit V.   +23 more
core   +1 more source

Selective induction of apoptosis in Philadelphia chromosome-positive chronic myelogenous leukemia cells by an inhibitor of BCR–ABL tyrosine kinase, CGP 57148 [PDF]

Cell Death & Differentiation, 1998
The BCR - ABL tyrosine kinase has been implicated as the cause of Philadelphia chromosome (Ph1)-positive leukemias. We report herein that CGP 57148, a selective inhibitor of the ABL tyrosine kinase, caused apoptosis specifically in bcr - abl-positive chronic myelogenous leukemia (CML) cells, K562 and KYO-1.
S, Dan, M, Naito, T, Tsuruo
openaire   +2 more sources

Eradication of chronic myeloid leukemia stem cells: a novel mathematical model predicts no therapeutic benefit of adding G-CSF to imatinib [PDF]

, 2009
Imatinib mesylate induces complete cytogenetic responses in patients with chronic myeloid leukemia (CML), yet many patients have detectable BCR-ABL transcripts in peripheral blood even after prolonged therapy.
A Foudi, A Gothot, A Strife, A Wilson, AHG Hamilton, AR Oller, Bayard Clarkson, BJ Druker, C Cobaleda, C Roche-Lestienne, CH Jamieson, Christophe Fraser, CL Sawyers, D Dingli, E Passegue, F Arai, F Michor, F Michor, F Michor, Franziska Michor, GB Bradford, H Glimm, HG Jorgensen, I Roeder, J Cashman, J Cortes, Jasmine Foo, JC Wang, JD Rowley, JF Apperley, KJ Hope, KW Orford, L Ponchio, M Holtz, Mark W. Drummond, ME Gorre, MJ Mauro, MW Drummond, N Uchida, NL Komarova, NL Komarova, NP Shah, P Rousselot, PS Kim, S Branford, S Branford, S Merante, SM Graham, T Higashi, T Holyoake, T Lapidot, T Reya, Tessa Holyoake, TL Holyoake, W Ghanima, WR Bruce, Y Wang   +56 more
core   +7 more sources

Chronic myelogenous leukemia presenting with Morel Lavallée lesion: A case report of a rare presentation

Clinical Case Reports, 2022
Chronic myelogenous leukemia is a myeloproliferative neoplasm characterized by the BCR‐ABL1 fusion gene and the development of the Philadelphia chromosome, which leads to an increase in granulocytes and bone marrow myeloid precursors in the blood, it can
Sara S. I. Mohamed, Hana Mahmoud Qasim, Ahmed Mahfouz, Maab A. Osman, Ashraf O. E. Ahmed, Safa H. Al‐Azewi, Mohamad A. Yassin, Shehab Fareed   +7 more
doaj   +1 more source

Excellent outcomes of 2G-TKI therapy after imatinib failure in chronic phase CML patients [PDF]

, 2018
open25noSecond-generation tyrosine kinase inhibitors (2G-TKIs) dasatinib and nilotinib produced historical rates of about 50% complete cytogenetic response (CCyR) and about 40% major molecular response (MMR) in chronic myeloid leukaemia (CML) patients ...

core   +1 more source

Analysis of Philadelphia chromosome-negative BCR-ABL-positive chronic myelogenous leukemia by hypermetaphase fluorescence in situ hybridization

Annals of Oncology, 1999
In 5%-10% of patients with of chronic myelogenous leukemia (CML), the Philadelphia chromosome (Ph) is not identified, despite the presence of the associated BCR-ABL molecular abnormality (Ph-negative, BCR-ABL-positive CML) because of sub-microscopic rearrangements.Six patients with Ph-negative, BCR-ABL-positive CML were investigated.
D, Seong, H M, Kantarjian, M, Albitar, R, Arlinghaus, J, Xu, M, Talpaz, M B, Rios, J Q, Guo, S, O'Brien, M, Siciliano   +9 more
openaire   +2 more sources

A long-lasting, complete hematologic and cytogenetic remission of chronic myelogenous leukemia after treatment with busulfan alone [PDF]

, 1996
A 44-year-old man suffering from cytogenetically and molecularly proven Philadelphia translocation-positive chronic myelogenous leukemia in chronic phase was treated with busulfan for 18 months and studied during a follow-up period of 13 years ...
Geurts van Kessel, A.H.M. (Ad), Haanen, C. (C.), Hagemeÿer, A. (A.), Mandigers, C., Mensink, E.J.B.M. (Ewald), Plas, D. (D.) van der, Witte, T. de   +6 more
core   +1 more source

Synergistic activity of the new ABL-specific tyrosine kinase inhibitor STI571 and chemotherapeutic drugs on BCR-ABL-positive chronic myelogenous leukemia cells [PDF]

Leukemia, 2001
The ABL-specific tyrosine kinase inhibitor STI571 (formerly CGP57148B) induced cytogenetic remissions in 33% of chronic myelogenous leukemia (CML) patients in a phase I trial (Druker et al 1999). Combination therapy may increase this proportion. We tested whether combinations of STI571 and cytarabine or other chemotherapeutic agents such as hydroxyurea,
J, Topaly, W J, Zeller, S, Fruehauf
openaire   +2 more sources

Mutational analysis of T315I in patients with chronic myeloid leukemia who did not respond to second-generation tyrosine kinase inhibitors

Iraqi Journal of Hematology, 2020
BACKGROUND: Chronic myelogenous leukemia (CML) is a hematological stem cell disorder that associates with mutations in BCR-ABL. Although mutations identified in more than 30 different amino acids, the highest degree of resistance was associated with ...
Riyam Qusay Ibrahim Al-Jadir, Jaffar Nouri Alalsaidissa   +1 more
doaj   +1 more source

Allogeneic stem cell transplant for chronic myeloid leukemia as a still promising option in the era of the new target therapy [PDF]

Vojnosanitetski Pregled, 2012
Background/Aim. Introducing tyrosine kinase inhibitors (TKIs) has essentially changed curative approach, to be precise, clearly improved treatment efficacy for chronic myeloid leukemia (CML).
Stamatović Dragana, Balint Bela, Tukić Ljiljana, Elez Marija, Tarabar Olivera, Todorović Milena, Todorić-Živanović Biljana, Ostojić Gordana, Tatomirović Željka, Marjanović Slobodan, Malešević Milomir   +10 more
doaj   +1 more source